Categories: DiagnosticsNews

Modi Ventures Raises $88 Million for Second Fund to Invest in Tech Bio Convergence

Oversubscribed close brings total committed capital to over $134 million to invest in companies and funds at the intersection of tech, bio, and medicine

HOUSTON, July 16, 2025 /PRNewswire/ — Modi Ventures, a venture capital firm founded in 2022 that backs companies at the intersection of artificial intelligence, biology and medical technology, today announced the close of $88 million of capital commitments with its second fund in an oversubscribed funding raise.

Modi Ventures is headquartered in the heart of Houston with offices at the 37-acre TMC Helix Park campus within the Texas Medical Center (TMC), the world’s largest medical ecosystem. Launched during a unique window of opportunity amid the market downturn of 2022, Modi Ventures swiftly raised over $30 million for its first fund in 2023. The firm has now closed its oversubscribed second fund in approximately three months, securing $88 million. Using proprietary and innovative financial engineering, the fund is designed to select resilient portfolios, consisting of funds and companies, to navigate volatility, as demonstrated during its launch period.

“Modi Ventures invests strategically at the convergence of technology and biology, employing a sophisticated and proprietary financial engineering framework rooted in modern portfolio theory and the efficient frontier principles,” said Sahir Ali, Modi Ventures’ solo general partner. “The second fund will continue to help build companies at the intersection of AI, biology, and medicine, focusing on pioneering advancements in digital biology and multi-omics, cellular reprogramming, AI-driven drug discovery, next-generation diagnostics, and therapeutics.”

“We’re proud to have witnessed the growth of Modi Ventures over the past few years at Helix Park, which is a cornerstone of Texas Medical Center’s vision to create a globally recognized hub for translational research and innovation,” said William McKeon, President and CEO of Texas Medical Center. “We look forward to continuing our partnership as we work together to build a world-class life sciences ecosystem right here in Houston.”

Initial investments include Lila Sciences, RTW Royalty Fund, Ignota Labs, Latus Bio and Flagship Pioneering.

About Modi Ventures

Modi Ventures Capital Management, located in Texas and managing $134 million, invests in innovators and companies shaping the future of humanity. The company’s primary investment focus is on emerging and disruptive AI and biomedical technologies. Investments in successful funds include Khosla Ventures, Section 32, Artis Ventures, Draper Associates, Yosemite and Abingworth.  Company investments and current holdings include Groq, Generate Biomedicines, Unnatural Products, Ozlo and Oklo. For more information, please visit www.modivc.com or follow us on LinkedIn.

Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/modi-ventures-raises-88-million-for-second-fund-to-invest-in-tech-bio-convergence-302505446.html

SOURCE Modi Ventures

Staff

Recent Posts

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…

4 hours ago

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…

4 hours ago

The Dot Corp Expands Services With New Promotional Products & Apparel Division

IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…

4 hours ago

Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals

CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…

4 hours ago

Biorep Technologies Announces First Successful Independent Research Use of the PRISM System in Islet Isolation

Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…

4 hours ago